Trial Profile
An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Acenocoumarol; Vitamin K antagonists; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Acronyms AXAFA; AXAFA-AFNET5
- 09 Feb 2022 Results published in the Circulation
- 16 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 20 Mar 2018 Primary endpoint (death and serious cardiovascular events) has been met as per the results published in the European Heart Journal.